NEW YORK (GenomeWeb News) – SRI International and Spyglass Technologies today announced an exclusive licensing deal to commercialize SRI's underwater mass spectrometry technology.

The agreement calls for St. Petersburg, Fla.-based Spyglass to apply SRI's in situ membrane introduction mass spec (MIMS) technology to "a broad range of commercial, research, and government applications." Additionally, Spyglass will bundle the MIMS device with other underwater sensors, and the partners will continue collaborating on applications of the technology for other markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.